Market likes what it sees as Alyzyme enters pivotal period

Drug developer Alizyme plc (AZM.L) this week reported it had halved interim net losses to £5.5m in the six months to end June from £10.1m in the same period in 2005.
 
It reported revenues of £1.1m compared to none previously. It had £22.8m in the bank at the end of June, down from £40.0m a year previously and £30.8m at the end of  December.

Summing up the half year, CEO Richard Palmer (pictured) said “we have continued the development of our late stage product portfolio. We are progressing Phase III clinical trials with renzapride for the treatment of constipation predominant irritable bowel syndrome and with COLAL-PRED for the treatment of active ulcerative colitis, and are preparing our third product, cetilistat, for Phase III clinical development for the treatment of obesity and related diseases.

“In addition, we are assessing the optimum route for the further development of ATL-104 for the treatment of mucositis, following its successful Phase IIa 'proof of concept' study.”

The Cambridge-based company’s research and development expenditure was £6.9m (2005: £9.1m). It expects R&D spending will be rise in the second half of 2006 reflecting the recruitment of patients into the two Phase III clinical trials currently being conducted.

Management and administration expenses were £0.6m (2005: £0.5m).

Outlook

“The next period will be pivotal for Alizyme as we seek to exploit the commercial value inherent in our late stage product portfolio, Dr Palmer said.

The market took heart from the update, marking the share price up almost 15% to 106.5p after a steady decline since the whole market got the yips in May, valuing the company at around £195m.

12th August 2006

Previous articles
ARM holds the line in Q3 2009, outperforms chip industry
Cambridge University’s Chemical Engineering, Biotech arms merge
Silicon Fen pioneers Cambridge Consultants celebrate 50 years
Silicon Fen Top 20, the Cambridge Cluster's own share price index, launched; will measure the collective bottom line
Briefs: CSR partners with Taiyo Yuden; Camrivox’s CTI for Skype beta available
AVEVA hits record results in 08/09; ‘better equipped’ to trade thru downturn
Briefs: CSR, Autonomy release new products: Phytopharm CEO, CFO leave; Dialight sees good progress
Bango H1 FY2010 revenue up 83%, losses narrow
Briefs: New Cambridge Uni Centre for Obesity; Autonomy snags Integrated Media Mgt as client for Cardiff
Autonomy tops £2 billion market cap as it forecasts another record quarter ahead
Subscribe

 

Managed Hosting by NTT Managed Hosting
SEO London by IdeaTaxi.com
Corporate profiles

 • Cavendish Laboratory


Prof Peter Littlewood
Head of Department


The Cavendish Laboratory, Department of Physics, Cambridge University was founded in 1871, along with the appointment of James Clerk Maxwell as the first Cavendish Professor. It has a distinguished intellectual history, with 29 Nobel prize winners who worked for considerable periods within its facilities,

[Cavendish Laboratory's profile]


Top20 Index




Currently: 130.81

Best Deal Mortgages
If debt is becoming a problem, click here for the best deal mortgages.

Marcus Evans conferences
See how Marcus Evans has helped many company employees expand their skills.

Scam Events for Marcus Evans
Register for one of the next anti-scam events for Marcus Evans and learn about ethical corporate culture.

IFL
IFL are leaders in the Chrome industry. To find out more visit www.ifml.com